U.S. patent application number 11/431663 was filed with the patent office on 2006-09-07 for compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof.
This patent application is currently assigned to ViroMed Co., Ltd.. Invention is credited to Seong-Hyun Ho, Jong-Mook Kim, Sunyoung Kim, Eun-Jin Park.
Application Number | 20060198826 11/431663 |
Document ID | / |
Family ID | 36932148 |
Filed Date | 2006-09-07 |
United States Patent
Application |
20060198826 |
Kind Code |
A1 |
Kim; Jong-Mook ; et
al. |
September 7, 2006 |
Compositions for gene therapy of rheumatoid arthritis including a
gene encoding an anti-angiogenic protein or parts thereof
Abstract
The present invention relates to the compositions for a gene
therapy of rheumatoid arthritis including a gene encoding an
anti-angiogenic protein or parts thereof. More specifically, the
present invention provides a gene therapy of rheumatoid arthritis
by preparing a recombinant vector that expresses a gene encoding an
anti-angiogenic protein such as endostatin or parts thereof, and
transplanting the recombinant vector or a cell that is transfected
or transduced with the recombinant vector into the affected area of
a patient, and also provides the compositions for the gene therapy.
The compositions for the gene therapy according to the present
invention can be used effectively for the treatment of rheumatoid
arthritis, for which effective treating methods have not been
developed until now, by providing the anti-angiogenic proteins into
the knee of a patient continuously to prevent the synovial tissue
hyperplasia and the resulting inflammation.
Inventors: |
Kim; Jong-Mook; (Seoul,
KR) ; Ho; Seong-Hyun; (Seoul, KR) ; Park;
Eun-Jin; (Seoul, KR) ; Kim; Sunyoung; (Seoul,
KR) |
Correspondence
Address: |
STERNE, KESSLER, GOLDSTEIN & FOX PLLC
1100 NEW YORK AVENUE, N.W.
WASHINGTON
DC
20005
US
|
Assignee: |
ViroMed Co., Ltd.
Seoul
KR
|
Family ID: |
36932148 |
Appl. No.: |
11/431663 |
Filed: |
May 11, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10220824 |
Aug 30, 2002 |
|
|
|
PCT/KR02/00001 |
Jan 3, 2002 |
|
|
|
11431663 |
May 11, 2006 |
|
|
|
Current U.S.
Class: |
424/93.2 ;
435/456; 514/44R |
Current CPC
Class: |
A01K 2267/0325 20130101;
C07K 2319/02 20130101; A61K 48/005 20130101; A61P 19/02 20180101;
A61P 29/00 20180101; A61K 48/00 20130101; A61K 38/195 20130101;
A61K 38/484 20130101; A61K 38/39 20130101; A61K 35/33 20130101;
C12N 15/86 20130101; A61P 43/00 20180101; C12N 2740/13043
20130101 |
Class at
Publication: |
424/093.2 ;
514/044; 435/456 |
International
Class: |
A61K 48/00 20060101
A61K048/00; C12N 15/86 20060101 C12N015/86 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 5, 2001 |
KR |
2001/0000691 |
Claims
1-14. (canceled)
15. A method of delaying the progression of one or more rheumatoid
arthritis-associated symptoms in a patient having rheumatoid
arthritis, wherein said symptoms are selected from the group
consisting of: (i) joint swelling, (ii) synovial hyperplasia, (iii)
cartilage destruction, and (iv) joint inflammation-associated
cytokine level; said method comprising directly injecting into one
or more sites of rheumatoid arthritis or sites adjacent thereto
within the same limb of the patient a sufficient amount of a
composition comprising: (a) a host cell comprising a nucleic acid
encoding endostatin or an anti-angiogenic fragment thereof, wherein
said nucleic acid is operably linked to a signal sequence encoding
a secretion peptide; and (b) a carrier; wherein said host cell is
transformed by a retroviral vector comprising said nucleic acid
operably linked to said signal sequence, and wherein said host cell
is histocompatible with said patient.
16. The method of claim 15, wherein said endostatin is derived from
human collagen XVIII, mouse collagen XVIII, rhesus collagen XVIII,
pig collagen XVIII, or bovine collagen XVIII.
17. The method of claim 16, wherein said endostatin is derived from
human collagen XVIII.
18. The method of claim 15, wherein said retroviral vector is
derived from the MT5 plasmid (KCCM Deposit No. 10205).
19. The method of claim 15, wherein said nucleic acid comprises the
nucleotide sequence represented by SEQ ID NO:8.
20. The method of claim 15, wherein said composition is injected
into a site within the same limb as and adjacent to a site of
rheumatoid arthritis.
21. The method of claim 20, wherein said composition is injected
into a knee of said patient.
22. The method of claim 21, wherein the progression of joint
swelling in an ankle of said patient is delayed.
Description
TECHNICAL FIELD
[0001] The present invention relates in general to compositions for
gene therapy of rheumatoid arthritis including a gene encoding an
anti-angiogenic protein or parts thereof, and more particularly to
a gene therapy for treating rheumatoid arthritis by constructing a
recombinant vector including a gene encoding an anti-angiogenic
protein or parts thereof and transplanting the recombinant vector
or the cells transfected or transduced with the recombinant vector
into the affected area of a patient, and compositions for the gene
therapy.
BACKGROUND ART
[0002] Rheumatoid arthritis is a chronic inflammatory disease
involving multiple joints. The main pathology of the affected
synovial tissue consists of the hyperplasia and the subintimal
infiltration of T and B lymphocytes. Such inflammation of the
synovial tissue is thought to be caused by T lymphocyte reactive to
an unknown autoantigen. Nonetheless, the T lymphocyte infiltrated
in the almost tissues does not show any indication of activation on
the surface of cell and also does not almost express cytokines. In
contrast to this, it is observed that both synovial tissue and
fluid are enriched with the cytokines derived from macrophage.
These cytokines may include interleukin-1 (IL-1) which can
accelerate the growth of synovial fibroblast and tumor necrosis
factors (TNFs). These experimental results suggest the hypothesis
that T lymphocyte is importantly associated with the induction of
inflammation to synovial tissues and the inflammation is maintained
by the cytokines derived from the activated synovial cells.
[0003] One of the major intents of rheumatoid arthritis treatment
is to prevent the synovial tissue hyperplasia, because it forms the
pannus tissue that irreversibly destroys the cartilage and bone in
the affected joint. Effective drugs for treating rheumatoid
arthritis have not been developed until the present time and the
developed drugs can exhibit limited efficacies. Once arthritis
occurs, it causes economic loss as well as severe pain.
[0004] Medical treatments of rheumatoid arthritis being used
presently are as follows. The drugs used often for initial
treatment are non-steroidal anti-inflammatory drugs (NSAIDs). These
NSAIDs limitedly improve a patient's condition, but cannot prevent
the cartilage destruction of joint area or the progress of disease.
Moreover, half the patients using this treatment should stop the
treatment within one year because of serious side effect. Next,
gold drugs such as gold sodium thiomalate and gold sodium
thiosulfate, or disease modifying anti-rheumatic drugs (DMARDs)
such as penicillamine and anti-malarials are used. These drugs also
decrease the progress of rheumatoid arthritis, but after 5 years of
the treatment using DMARDs, only 5-15% of the patients adhere to
use the drugs because the serious side effect can be accompanied.
If the drugs mentioned above are not effective any more, the
affected joint area with rheumatoid arthritis should be replaced by
artificial joint by surgical operation.
[0005] In this manner, most of the treatments of rheumatoid
arthritis used until now were not designed with a particular target
molecule and had a limitation of showing slight effects in most
cases. In the meantime, it has been reported that therapeutic
effects appeared by taking notice of inflammation-inducing
cytokines such as TNF as a target molecule for treating the
rheumatoid arthritis and introducing an antibody specific to TNF or
a soluble TNF-receptor into the affected area of a patient to
result in inactivation of the TNF (Maini, R. N. et al., Immunol.
Rev. 144:195, 1995; Moreland, L. W. et al., N. Engl. J. Med.
337:141, 1997). In company with this, various gene transfer
experiments in vivo are progressing in an animal model of
rheumatoid arthritis with continuously expressing the molecules
having an immune inhibitory function. Consequently, most of the
current treatments are directed to correction of the immune
aberration that supposedly drives the synovial cell
proliferation.
[0006] Angiogenesis, the formation of new blood vessels, is one of
the earliest histopathologic findings in rheumatoid arthritis and
appears to be required for pannus development. This
neovascularization is thought not only to maintain the chronic
architectural changes via delivery of required blood-borne elements
to the pannus, but also to play an active role in inflammation as a
source of both cytokine and protease activity. The expanded
vascular-bed volume resulting from angiogenesis may provide
increased access for inflammatory cells to infiltrate the synovium.
Although the factors specifically promoting angiogenesis in
rheumatoid arthritis have not yet been identified, both synovial
tissue and fluid are enriched with angiogenesis-promoting
molecules. These include cytokines, such as basic fibroblast growth
factor (bFGF), interleukin-8 (IL-8), vascular endothelial growth
factor (VEGF), and soluble adhesion molecules, such as E-selectin.
These data suggested a therapeutic potential for using an
anti-angiogenic procedure for favorably changing the disease course
of rheumatoid arthritis.
[0007] Until now a lot of factors that repress angiogenesis have
been found. Most of them are created from the cleavage of
protoprotein, and representatively angiostatin, endostatin and
platelet factor-4 and the like have been known.
[0008] Angiostatin is composed of 98.sup.th to 440.sup.th amino
acids of plasminogen. Angiostatin was initially isolated from mice
bearing a Lewis lung carcinoma and was identified as a 38-kDa
internal fragment of plasminogen that encompasses the first four
kringles of the molecule (O'Relly, M. et al., Cell 79:715, 1994).
It was reported that the growth of primary tumors was inhibited
effectively by injecting purified angiostatin hypodermically in six
cancer model experiments (O'Relly, M. et al., Nat. Med. 2:689,
1996).
[0009] Endostatin consists of C-terminal 183 amino acids of
collagen XVIII and has an anti-angiogenic activity. It was reported
that the growth of primary tumors was inhibited effectively by
injecting purified endostatin hypodermically in four cancer model
experiments (O'Relly, M. et al., Cell 88:277, 1997).
[0010] Platelet factor-4 belongs to CXC cytokine family, which
consists of chemotactic polypeptides below 10 kDa, and has an
anti-angiogenic activity. It was reported that the platelet
factor-4 inhibited the growth of cancer, such as B-16 melanoma and
HCT-116 colon carcinoma (Maion, T. E. et al., Cancer Research,
51:2077, 1991).
[0011] Angiogenesis is known to be associated with various
diseases, such as tumor formation and metastasis, retinitis,
angioma, chronic inflammation, intestinal adhesions,
atherosclerosis, rheumatoid arthritis and so on, but it has not yet
been verified that anti-angiogenic factors were effective to all
the diseases listed above actually. Only the tumor inhibitory
effects of these factors associated with a particular disease have
been reported (U.S. Pat. No. 5,856,315, U.S. Pat. No. 5,733,876,
U.S. Pat. No. 5,792,845, U.S. Pat. No. 5,854,205, U.S. Pat. No.
6,024,688). The US patents disclose that the treatment effects for
various kinds of diseases, such as ovarian carcinoma (HTB161,
A2780S), colon carcinoma (MIP, CACO2), Lewis Lung Carcinoma (LLC),
fibrosarcoma (T241), prostate gland carcinoma (PC-3) and breast
carcinoma (MDA-MB), were identified by injecting anti-angiogenic
factors with the type of recombinant protein.
[0012] Meanwhile, unlike general treating method that applies a
toxicity to cells directly, the treating method, which cures
diseases by inhibiting angiogenesis by means of supplying
anti-angiogenic factors as described above, is based on the
principle of inhibiting the cell growth, so anti-angiogenic factors
over certain concentration should be supplied continuously to
exhibit effects in vivo. But, the method of supplying
anti-angiogenic factors with the type of recombinant proteins costs
too much for administering proteins continuously, is troublesome
and has a problem in that it imparts toxicity to a patient.
Therefore, it has been required to develop a method of supplying
anti-angiogenic factors to the affected area continuously and
locally.
[0013] Accordingly, the present inventors have attempted new
approaches for the probability of the treatment of rheumatoid
arthritis by anti-angiogenesis in order to replace the prior
treatment of rheumatoid arthritis having focused on solving the
immunological problems. More particularly, the present inventors
obtained the cell lines for producing representative
anti-angiogenic factors such as angiostatin, endostatin and
platelet factor-4 through inserting their genes into a viral vector
and then transplanting them the affected area of mice induced with
rheumatoid arthritis. We also performed the histological
examinations for the level of hyperplasia in synovial cell and
cartilage destruction and the immunological examinations for the
concentrations of cytokines associated with the joint inflammation,
as well as macroscopic examination for joint swelling to obtain the
results for the progressive level of rheumatoid arthritis. The
results showed that the incidence of rheumatoid arthritis in our
treatment was remarkably reduced in comparison with the control
group. This is to show that our gene therapy using an
anti-angiogenic gene is effective to treatment of rheumatoid
arthritis.
DISCLOSURE OF THE INVENTION
[0014] It is therefore an object of the present invention to
provide compositions for gene therapy of rheumatoid arthritis
including a DNA encoding an anti-angiogenic protein or parts
thereof. More particularly, the present invention provides a
recombinant vector including a DNA encoding an anti-angiogenic
protein or parts thereof, a cell into which the recombinant vector
is introduced and compositions for the gene therapy of rheumatoid
arthritis including the recombinant vector or the recombinant cell
as an active ingredient.
[0015] To accomplish this object, the present invention provides
compositions for gene therapy including a DNA encoding an
anti-angiogenic protein or parts thereof, which shows therapeutic
effects on rheumatoid arthritis.
[0016] According to the compositions of the present invention, the
DNA encoding an anti-angiogenic protein or parts thereof can be
provided with an inserted form in retroviral vector, adenoviral
vector, adeno-associated viral vector, herpes simplex viral vector
or plasmid that can be expressed in an animal cell, or with the
form of a recombinant cell that is collected by transfecting or
transducing a cell with the recombinant vector including the DNA in
order to supply anti-angiogenic factor to the affected area
continuously and locally.
[0017] Furthermore, the present invention provides a gene therapy
of treating rheumatoid arthritis by delivering the compositions to
the affected area of a patient.
[0018] As used herein, the term "anti-angiogenic gene" means a DNA
encoding an anti-angiogenic protein or parts thereof. It is not
limited to a natural DNA, but may include any forms of proper
modifications under maintenance of anti-angiogenic activity and
additions of elements for expression regulation if it can be used
suitably for the purpose of the present invention, regardless of
whether or not it is obtained by genetic engineering method or
chemical method.
[0019] Hereinafter, the present invention will be described in
detail.
[0020] The present invention is characterized in that the
composition for gene therapy of treating arthritis comprises a DNA
encoding anti-angiogenic protein or parts thereof as an active
ingredient. The anti-angiogenic gene used in the gene therapy for
treating arthritis according to the present invention is preferably
a gene encoding at least one protein selected from the group
consisting of angiostatin, endostatin, platelet factor-4,
thrombospondin-1, thrombospondin-2, METH-1, METH-2 (anti-angiogenic
proteins having metalloprotease domain and thrombospondin domain;
Vanzquez F. et al., J. Biol. Chem. 274(33):23349-57, 1999) and
hepatocyte growth factor.
[0021] Particularly, the anti-angiogenic gene included in the
composition for gene therapy of treating arthritis according to the
invention is preferably the gene encoding the angiostatin including
98.sup.th to 440.sup.th amino acids of human plasminogen and the
four kringles, the gene encoding the endostatin including
1334.sup.th to 1516.sup.th amino acids of human collagen XVIII, or
the gene encoding the mouse platelet factor-4 protein.
[0022] Although an entire amino acid sequence may be used as the
anti-angiogenic factor, a fragment known as having anti-angiogenic
activity may also be used. For example, angiostatin kringle 1-3
fragment may be used for this purpose.
[0023] The example of the anti-angiogenic gene included in the
composition for gene therapy of treating arthritis according to the
invention may preferably be the DNA derived from human, mouse,
rhesus, pig or bovine plasminogen, and more preferably the cDNA of
human angiostatin. The endostatin gene may also preferably be the
DNA derived from human, mouse, rhesus, pig or bovine collagen
XVIII, and more preferably the cDNA of human endostatin. The
preferable embodiments of the invention identified that the
angiostatin and endostatin genes cloned from human foreskin
fibroblast (HFF) are effective to gene therapy for treating
arthritis.
[0024] The recombinant vector included in the composition for gene
therapy for treating arthritis according to the invention also
comprises the anti-angiogenic gene. It is preferable that the
recombinant vector further comprises a nucleotide sequence encoding
a signal peptide required for secretion in the upstream or
downstream in order to secrete the protein expressed by the gene
out of the cell.
[0025] The signal peptide may include any signal peptides known as
associated to protein secretion in eukaryotic cell, and may
preferably be 18 of amino-terminal amino acids of human plasminogen
represented as the SEQ ID No. 2 or the signal peptide of mouse
immunoglobulin .kappa. chain encoded by the nucleotide sequence
represented as SEQ ID No. 13.
[0026] For example, as described below in one preferable example
according to the invention, the signal sequence can be functionally
connected to the anti-angiogenic gene by synthesizing a nucleotide
including the nucleotide sequence encoding 18 of the amino-terminal
amino acids of human plasminogen and the sequences having
restrictive enzyme cleaving sites, hybridizing it into double
helical DNA, and treating it with restrictive enzyme to insert it
into a certain site of target vector. However, the construction of
vector having a signal sequence for producing the secretion type of
anti-angiogenic protein is not limited to as mentioned above, but
may be accomplished by the method well known in the field of this
art.
[0027] The vector used in the composition for gene therapy of
treating arthritis according to the invention is a vector in which
the anti-angiogenic gene can be inserted to supply the
anti-angiogenic factor continuously to the affected area. The
vector may include virus-derived vectors such as retroviral vector,
adenoviral vector, adeno-associated viral vector, and herpes
simplex viral vector, plasmids capable of being expressed in bodies
of animals such as pCXN2 (Gene, 108:193-200, 1991) and PAGE207
(Japan Patent Laid-Open No. Sho6-4684), and their modified
vectors.
[0028] In the preferable example according to the present
invention, a viral vector was prepared, which was to produce
angiostatin, endostatin or platelet factor-4 as a anti-angiogenic
factor, using MT5 retroviral vector which had been filed before
Korean Industrial Property Office (KIPO) by the present inventors
(Korean Patent Appl. No. 9748095; KCCM-10205), and the effect for
treating arthritis was verified by experimental results as to mouse
using the viral vector. The MT5 retroviral vector is a vector based
on murine leukemia virus (MLV) including mutant noncoding sequence
of human elongation factor 1 (EF 1), without coding sequence
derived from virus and is good in both external gene expressing
efficiency and viral titer. That is to say, the vector is to
enhance stability by completely removing the gag, pol and env
sequence of MLV, is to include at the upstream of external gene
insertion site, a part of noncoding sequence of EF 1a as a
noncoding sequence derived from heterogeneous gene for providing
splicing receptor, and is to control splicing efficiency
appropriately to maintain gene expressing highly with also
maintaining virus producing concentration highly.
[0029] Particularly, in one example of the present invention,
angiostatin DNA fragment encoding 93.sup.rd to 368.sup.th amino
acids of human plasminogen represented as SEQ ID No. 2 was obtained
from human foreskin fibroblast (HFF) through PCR and was inserted
into pGEM T easy vector to construct pGEM T easy-hASTi vector. The
sequence encoding 18 of amino-terminal amino acids of plasminogen
of SEQ ID No. 2 was synthesized as a signal sequence, and was
inserted into pGEM T easy-hASTi vector to construct pGEM T
easy-hAST vector. The obtained vector was cleaved with BamHI to
prepare human angiostatin gene fragment connected with the signal
sequence, which was inserted into MT5 vector. In the meantime, to
prepare cell lines expressing human angiostatin, MT5-hAST vector
DNA was transfected into 293T cell with the plasmid expressing
gag-pol and env gene of murine leukemia virus and then non-cellular
virus was obtained from the cell culture media.
[0030] The obtained virus was transduced into NIH3T3, and then the
cell lines introduced with retrovirus were selected and cultivated
to prepare NIH3T3 cells expressing human angiostatin protein. By
means of the same method, NIH3T3 cells expressing human endostatin
protein and mouse platelet factor-4 protein were prepared
respectively.
[0031] Another example of the present invention verified the effect
of gene therapy for arthritis using the cell lines respectively
expressing anti-angiogenic proteins such as human angiostatin
protein, human endostatin protein and mouse platelet factor-4
protein.
[0032] Particularly, a gene therapy to mice without any macroscopic
signs of inflammation in collagen-induced arthritis mouse model was
performed. Namely, anti-angiogenic protein-producing NIH3T3 cell
lines mixed with PBS were transplanted in the knee joint area of
rear leg of the arthritis-mouse, and then the progressive level of
arthritis was investigated by measuring joint swelling, synovial
hyperplasia, destruction of cartilage, and joint
inflammation-associated cytokine level.
[0033] The results showed that the swelling level in the knee joint
area in case of transplanting angiostatin-producing NIH3T3 cell
lines was remarkably decreased to 27% in comparison that the
control group in case of injecting only PBS or transplanting the
cell lines transferred with only MT5 vector was 47% or 67%. The
frequency showing the significant level of IL-1 was also remarkably
decreased. The synovial hyperplasia and cartilage destruction in
the knee joint area were also remarkably decreased. Furthermore,
similar results to the transplant of antiostatin producing NIH3T3
cell lines were obtained when endostatin producing NIH3T3 cell
lines and platelet factor-4 producing NIH3T3 cell lines were
transplanted. These results show that the gene therapy using
anti-angiogenic gene according to the present invention is
effective to suppression and treatment of arthritis.
[0034] In another example of the present invention, duration of
therapeutic effects was measured. The result showed that
therapeutic effect of a single injection lasts for 14 days after
treatment.
[0035] The composition of gene therapy for treating arthritis
according to the present invention can be prepared by preparing
viral particles including recombinant DNA encoding anti-angiogenic
protein or cell lines transduced with the viral particles and
mixing them with carriers used in gene therapy (Crystal R G et al.,
Nature Genet. 8:42-51, 1994).
[0036] The carriers used in gene therapy may include any carriers
generally used in injection liquid. For example, the carriers may
include distilled water, sodium chloride solutions, the mixtures of
sodium chloride and inorganic salts or their similar mixtures, the
solutions of materials such as mannitol, lactose, dextran, and
glucose, amino acid solutions such as glycine and arginine, the
mixtures of organic acid solutions or salt solutions and glucose
solutions, and their similar solutions. The injection liquid may be
prepared in the form of solution, suspension or colloidal solution
by adding osmotic modulator, pH controller, vegetable oil such as
sesame oil or bean oil, lecithin or surfactant such as non-ionic
surfactant to the carriers in the conventional manners. This
injection may be prepared in the form of powder or lyophilization
and then dissolved in the form of solution before being used.
[0037] The composition of gene therapy for treating arthritis
according to the present invention may be dissolved in a sterilized
carrier, in case of solid phase, if needed, before treatment of
gene therapy, or may be used as it is without further treatment in
case of liquid phase.
[0038]